IRVING, Texas--(BUSINESS WIRE)--biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization ...

biote Corp. returned to profitability in Q3 2023 and is expected to continue to be profitable in the future. The company's growth is driven by the sale of hormone replacement therapy products and its ...

IRVING, Texas, May 07, 2025--Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today ...

I maintain my Strong Buy rating on biote Corp. due to its promising growth prospects, despite ongoing restructuring and short-term earnings pressure. The company’s vertical integration, digital ...

When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase stock, like in biote Corp.'s (NASDAQ:BTMD) instance, it's good news for shareholders.

CEO Bret Christensen noted that "the second quarter was pivotal for Biote as we implemented a strategic organizational restructuring designed to drive increased and sustainable growth." He highlighted ...

IRVING, Texas - Biote Corp. (NASDAQ: BTMD), a preventive health care company specializing in personalized hormone optimization, has reached a settlement with its founder, Dr. Gary S. Donovitz, ...

Biote Corp. ((BTMD)) has held its Q3 earnings call. Read on for the main highlights of the call. Biote Corp.’s latest earnings call revealed a mixed sentiment, with challenges and opportunities ...

Biote CEO Terry Weber moved to Dallas from Orange County, Calif., in 2018 to lead the hormone replacement therapy provider into its next stage of growth. The Irving-based company is expecting up to ...

Biote Corp (BTMD) reported its second-quarter earnings for 2025, surpassing earnings per share (EPS) expectations but falling short on revenue forecasts. The company posted an EPS of $0.10, exceeding ...